


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hastings et al.

Application Serial No.: 09/037,460

Filed: March 10, 1998

For: Human Vascular IBP-Like
Growth Factor Polynucleotides (Amended)



Art Unit: 1646

Examiner: Saoud, C.

Attorney Docket No.: PF147D1

Handwritten notes and stamps in the top right corner, including "1/15/2017", "PT 646", "1-18-00", and a signature.

RESPONSE UNDER 37 C.F.R. § 1.116 TO PAPER NO. 13

Assistant Commissioner for Patents

Washington, D.C. 20231

RECEIVED

DEC 28 1999

Sir:

TECH CENTER 1600/2900

In response to the final Official Action mailed October 26, 1999 (Paper No. 13), applicants hereby request that the following amendments and remarks be entered into the above-captioned application. Applicants submit concurrently herewith: (a) a Fee Transmittal Sheet; (b) a Supplemental Information Disclosure Statement and Form PTO-1449 with copies of references AA-AG; and (c) a Petition Under 37 C.F.R. 1.17(i). Please amend the application as follows:

ok to enter as 1/17/00

In the Claims

Please cancel claims 93-100, 113, and 114 without prejudice.

Please amend the following claims.

108. (Twice amended) An isolated polynucleotide comprising a nucleic acid selected from the group consisting of:

- (a) a nucleic acid encoding amino acids +30 to +44 of SEQ ID NO:2;
- (b) a nucleic acid encoding amino acids +55 to +69 of SEQ ID NO:2;
- (c) [a nucleic acid encoding a polypeptide fragment of SEQ ID NO:2 or a polypeptide fragment encoded by the cDNA contained in ATCC Deposit No. 75874, wherein

DI